Application Of Cannabis In The Human Body Jadiam Lopez Aspen

Application of Cannabis in the Human Body Jadiam Lopez Aspen University N490 – Issues and Trends in Professional Nursing

Applying the core instructions from the provided content, this paper explores how cannabis interacts with the human body through the endocannabinoid system (ECS) and examines its medical applications, mechanisms, and delivery methods. The discussion contextualizes the significance of cannabis research amid the ongoing opioid crisis and evolving treatment modalities. It also reviews the historical background, physiological mechanisms, and clinical implications of cannabis use, especially focusing on cannabidiol (CBD) and tetrahydrocannabinol (THC).

Understanding the application of cannabis in the human body is critical due to its expanding role in medical treatment and the need to address opioid dependence. The opioid epidemic has highlighted the necessity for alternative pain management therapies, and cannabis derivatives such as CBD are increasingly seen as potential options. Historically, cannabis has been used medicinally for thousands of years, with modern scientific research confirming its efficacy in various health conditions.

Introduction

The use of cannabis for medicinal purposes has gained renewed interest amidst a global opioid crisis that underscores the need for alternative pain management strategies. While opioids have historically been prescribed for severe pain, their potential for dependency and overdose fatalities has prompted healthcare providers and researchers to explore other options, including cannabinoids derived from cannabis. This paper discusses the physiological mechanisms through which cannabis interacts with the human body, particularly focusing on the endocannabinoid system (ECS), as well as the history, therapeutic potential, and current methods of cannabis delivery.

The importance of understanding cannabis’s influence on the ECS provides insights into its potential to manage pain, inflammation, and other health conditions. By exploring the biological basis of cannabis action, the paper contributes to an informed perspective on its medical utility and safety considerations.

Literature Review / Search

Current literature was sourced using databases such as PubMed, ProQuest, and Google Scholar, employing keywords including "cannabis," "endocannabinoid system," and "medical cannabis." The selection was limited to peer-reviewed articles published within the last five years, with a total of 534 initial results, narrowed for relevance. This methodological approach ensures that the discussion reflects the latest scientific findings and clinical evidence regarding cannabis and its physiological interactions.

This literature review highlights the scientific foundation of cannabis’s mechanisms in the human body, focusing on the roles of THC and CBD, their receptor targets, and the implications for treatment of various disorders.

Endocannabinoid System and Cannabis

The endocannabinoid system (ECS) is a complex network of receptors, endogenous ligands, and enzymes that regulate numerous physiological processes, including mood, appetite, pain sensation, immune function, and homeostasis. The two primary receptors, CB1 and CB2, play distinct roles: CB1 receptors are predominantly located in the Central Nervous System (CNS), influencing emotions, memory, and coordination, whereas CB2 receptors are mainly found in the immune system and peripheral tissues, modulating inflammation and immune response.

THC, the psychoactive component of cannabis, primarily targets CB1 receptors, producing the characteristic "high" by influencing neural pathways associated with pleasure, reward, and perception. It also affects CB2 receptors, contributing to anti-inflammatory effects. In contrast, CBD primarily interacts with CB2 receptors, exerting therapeutic effects such as reduction of inflammation, pain relief, and anxiolytic properties without producing intoxication. This complementary action of THC and CBD signifies their potential combined use in various medical conditions.

The ECS operates similarly to the endogenous opioid system yet differs in its molecular mechanisms, emphasizing its broader regulatory capacity in maintaining physiological balance. The discovery of the ECS in the 1990s has revolutionized understanding of cannabis’s pharmacology, establishing its vital role in health and disease management.

Research over five decades has demonstrated that cannabis effectively modulates the ECS, influencing disease pathways and symptom management. The activation of CB1 and CB2 receptors by phytocannabinoids like THC and CBD results in varied effects, from pain alleviation to neuroprotection, making cannabis a promising agent in therapeutics.

Clinical Endocannabinoid Deficiency Syndrome

Disruptions in the ECS, known as Clinical Endocannabinoid Deficiency Syndrome (CEDS), are hypothesized to underlie several chronic conditions including migraines, fibromyalgia, and irritable bowel syndrome. CEDS is characterized by reduced endocannabinoid levels or receptor activity, leading to impaired regulatory functions. This deficiency can result from various factors such as chronic stress, poor diet, or environmental toxins, causing imbalance across multiple bodily systems.

When the ECS is out of equilibrium, physiological processes such as immune regulation, mood stabilization, and pain modulation become dysregulated, contributing to persistent symptoms and disease states. For example, migraine sufferers often exhibit reduced endocannabinoid activity, which can be ameliorated with cannabinoid supplementation, restoring balance in neurovascular regulation.

Addressing ECS deficiencies may involve pharmacological interventions like cannabis or cannabinoids, alongside lifestyle modifications such as exercise, diet, and stress management, which naturally support ECS functionality. For instance, physical touch and social bonding, such as hugging, have been shown to release endorphins and enhance ECS activity, underscoring the importance of a holistic approach to treatment.

Methods of Treatment and Delivery Routes of Cannabis

Cannabis can be administered via various routes, each with different onset times, bioavailability, and therapeutic potentials. The main delivery methods include inhalation, oral ingestion, transdermal patches, and rectal suppositories.

Inhalation involves smoking or vaporizing cannabis, offering rapid onset within minutes and flexible dosing. However, concerns over respiratory health, particularly lung damage and tar inhalation, have prompted the development of regulated inhalation devices to mitigate risks.

Oral administration, through capsules, tinctures, or edibles, provides a convenient, non-invasive method with longer-lasting effects but slower onset—typically 30 to 90 minutes—due to gastrointestinal absorption. This slower onset necessitates dosing carefully to avoid accidental overdose; however, oral delivery may lead to variable bioavailability due to first-pass hepatic metabolism.

Transdermal patches and topical oils allow cannabinoids to penetrate the skin, providing localized relief with a gradual onset but potentially longer duration. This method is particularly advantageous for targeted pain relief, as in the case of arthritis or post-surgical inflammation.

Rectal suppositories, though less common, enable direct absorption into systemic circulation through rectal mucosa, bypassing hepatic first-pass metabolism, providing relatively rapid effects. Nonetheless, this route is often limited by discomfort and risk of infection.

Emerging delivery systems aim to optimize therapeutic outcomes by balancing rapid onset with safety, including nanoemulsions, liposomes, and inhalers, reflecting ongoing innovations in cannabis pharmacotherapy.

Conclusion

The application of cannabis in the human body demonstrates significant therapeutic potential through its interaction with the endocannabinoid system. Understanding the mechanisms involving CB1 and CB2 receptors helps clarify how phytocannabinoids like THC and CBD exert their effects, from psychoactive experiences to anti-inflammatory and analgesic actions. The concept of Clinical Endocannabinoid Deficiency Syndrome explains the pathophysiological basis for some chronic conditions, highlighting the importance of restoring ECS balance through cannabis-based therapies.

Delivery routes, tailored to specific medical needs and patient preferences, play a vital role in maximizing treatment efficacy while minimizing adverse effects. The rapid advancement of delivery methods and ongoing research into ECS and cannabinoid pharmacology underscore the evolving landscape of medical cannabis. As healthcare agencies continue to endorse evidence-based practices, cannabis could increasingly serve as a valuable component in comprehensive treatment plans, ultimately contributing to improved patient outcomes and reduced dependency on opioids.

In summary, a deeper understanding of cannabis’s biological effects and safe administration strategies is essential for integrating this ancient plant into modern medical practice responsibly.

References

• Grotenhermen, F. (2001). Harm Reduction Associated with Inhalation and oral Administration of Cannabis and THC. The Haworth Press Inc.
• Introduction to the Endocannabinoid System. (2020, June 29). NORML. https://norml.org
• MacCallum, C. A., & Russo, E. B. (2018). Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine, 49, 12–19.
• Ramkellawan, S., Bober, S., Mindra, S., Moreau, J., & Ko, G. (2016). Medical cannabis—the Canadian perspective. Journal of Pain Research, Volume 9.
• Russo, E. B. (2016). Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis and Cannabinoid Research, 1(1).
• Hurd, Y. L., & Yoon, M. (2016). The endocannabinoid system in neurodegenerative disorders. Trends in Pharmacological Sciences, 37(4), 369–380.
• Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013). The empirical foundation of medical cannabis and cannabinoids: A review. Journal of Clinical Medicine, 2(4), 351–372.
• Hill, K. P., & Palastro, M. D. (2017). Medical cannabis: A review of its use in chronic pain management. Current Pain and Headache Reports, 21(9), 45.
• Whiting, P. F., Wolff, R. F., Deshpande, S., et al. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA, 313(24), 2456–2473.
• Naftali, T., & Dabby, R. (2017). Medical cannabis for inflammatory bowel disease: An overview. European Journal of Gastroenterology & Hepatology, 29(6), 719–725.